AMT-676 is under clinical development by Multitude therapeutics and currently in Phase I for Pancreatic Ductal Carcinoma. According to GlobalData, Phase I drugs for Pancreatic Ductal Carcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the AMT-676 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AMT-676 overview
AMT-676 is under development for the treatment of colorectal cancer, gastric cancer, esophageal adenocarcinoma, cholangiocarcinoma, pancreatic ductal cancers, neuroendocrine tumors and unspecified cancer. The drug candidate is an antibody-drug conjugate and is being developed based on MabArrayTM technology.
It was also under development for gastric cancer, colorectal cancer and pancreatic cancer.
Multitude therapeutics overview
Multitude therapeutics Inc is a Pharmaceuticals and Healthcare company that Develop antibody-drug conjugates. The company is headquartered in Los Angles, California, The U.S.
For a complete picture of AMT-676’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
